Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

ACADEMY OF MANAGED CARE PHARMACY

UEI: CAKBZB9JUF71CAGE: 4FCN4

ACADEMY OF MANAGED CARE PHARMACY is a federal contractor, registered under UEI CAKBZB9JUF71 and CAGE code 4FCN4. It has been awarded $2,763,968 across 2 federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

CAKBZB9JUF71

CAGE Code

4FCN4

Entity Structure

Corporate Entity (Tax Exempt)

Established

N/A

Business Classifications

A8

NAICS Codes

813920Professional Organizations(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Academy of Managed Care Pharmacy specializes in advancing policy, research, and operational frameworks within the managed care pharmacy sector to support public health objectives. Their core capabilities center on evidence-based formulary design, utilization management strategies, pharmacy benefit o...

Academy of Managed Care Pharmacy specializes in advancing policy, research, and operational frameworks within the managed care pharmacy sector to support public health objectives. Their core capabilities center on evidence-based formulary design, utilization management strategies, pharmacy benefit optimization, and health economics analysis for government-funded programs. The organization provides technical advisory services in drug pricing transparency, prior authorization protocols, and clinical guideline integration, with deep expertise in Medicaid and Medicare Part D program dynamics. Their differentiation lies in bridging clinical pharmacy practice with public policy implementation, ensuring that pharmaceutical access aligns with fiscal sustainability and patient outcomes. They are uniquely positioned to translate complex pharmacoeconomic data into actionable policy recommendations for federal and state health agencies. Award history does not provide sufficient detail to identify specific agencies or contracting patterns. Consequently, no verifiable agency relationships or programmatic engagements can be confirmed from available data. The primary NAICS code 813920 classifies the entity as an “Other Similar Organizations (Except Business, Professional, Labor, and Political Organizations),” indicating its role as a professional association or trade group focused on managed care pharmacy. In practice, this means the organization operates as a non-profit industry consortium that fosters collaboration among pharmacists, payers, and policymakers to improve medication use in public health systems. Their market positioning is rooted in thought leadership and consensus-building rather than direct service delivery. The entity is structured as an 8H — a non-profit, non-governmental organization — with its headquarters in Alexandria, Virginia. It holds no federal certifications and operates without a commercial contracting footprint. Its influence stems from its role as a knowledge hub and standards-setting body within the managed care pharmacy ecosystem, serving as a neutral platform for stakeholder alignment rather than a traditional federal contractor.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services$2.8M100%
Awards by NAICS
- Unknown NAICS$2.8M100%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in ACADEMY OF MANAGED CARE PHARMACY's top NAICS codes and agencies

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Department of Health and Human Services

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Department of Health and Human Services

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Department of Health and Human Services

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
Federal
Vehicle Recompete: Idc 75N95022D00017This contract is an indefinite delivery contract vehicle (IDC) with the identifier 75N95022D00017, overseeing the ordering period from September 5, 2022, through September 4, 2027. It supports the National Institute on Drug Abuse (NIDA) data, statistics, and clinical trial operations under the Department of Health and Human Services, managed by the National Institutes of Health (NIH). The contract has a ceiling value of approximately $44.3 million and does not involve any set-aside provisions. It represents a full recompete classification, indicating a competitive solicitation process to award the contract. Currently, there are no active task orders valued at zero, but several significant task orders have been executed under this vehicle. Several key task orders highlight the contract’s scope and value, all awarded to The Emmes Company, LLC. These task orders cover a variety of research and analytical services, including the management and support of the Data and Statistics Center (DSC) from March 2025 to February 2026 ($1.85 million), data analysis related to GLP-1 as an adjunct to buprenorphine from May 2025 to February 2028 ($1.4 million), and various other clinical and secondary analysis projects concerning opioid use disorder and related research, with task order values ranging from approximately $375,000 to $800,000. The work performed under these task orders reflects a comprehensive support framework for clinical trials and data management activities essential to advancing research efforts around drug abuse and treatment strategies.
National Institutes Of Health Nida

POSTED

6 months ago

DEADLINE

N/A
View Details